N/A N=104 A Device Study for the Treatment of Acne
Acne Vulgaris
Primary: Percentage of Participants Achieving Treatment Success — 81 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=15 Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations
Choroideremia · CHM (Choroideremia) Gene Mutations
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 5; 5; 5 Participants
N/A N=24 Bioequivalence Study of Furosemide 40 mg Tablet in 24 Indonesian Healthy Volunteers
Drug Use
Primary: Geometric Mean Ratio of Maximum Concentration — 104.51 percentage
Phase 2 N=202 Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Osteoarthritis
Osteoarthritis
Primary: Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) — -1.67; -1.76 score on a scale
Phase 1 N=24 Evaluate the Pharmacokinetics, Safety, and Tolerability of Nirsevimab in Healthy Chinese Adults
Evaluate PK Profile
Primary: Serum Concentrations of Nirsevimab — NA; 27.644; 41.794; 43.811 micrograms/milliliter (mcg/mL)
N/A N=5 Intervention Mapping to Adapt a Mindfulness-based Intervention for Adults With Diabetes and Emotional Distress
Type 2 Diabetes · Stress
Primary: Diabetes Distress — 2.64 score on a scale
N/A N=408 Coaching Alternative Parenting Strategies (CAPS) Study
Child Abuse · Self-control · Parenting
Primary: DPICS-IV Observed Parenting Skills (During Child-Led Play) — 2.32; 2.63; 2.86; 2.11 number of behaviors
N/A N=152 Clinical Comparison of Two Daily Disposable Toric Soft Contact Lenses
Astigmatism · Ametropia · Myopia
Primary: Least Squares Means Distance Visual Acuity With Study Lenses at Week 1 — -0.11; -0.10 logMAR
Phase 3 N=1,428 A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
Type 2 Diabetes
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) — -2.26; -1.16 Percentage of HbA1c — p=<0.001
Phase 2 N=387 A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight
Obesity
Primary: Percentage Change in Body Weight From Baseline to Week 46 — -6.19; -12.51; -13.22; -14.94 Percentage change — p=<0.0001
Phase 2 N=153 Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Chronic Low Back Pain
Chronic Low-back Pain
Primary: Change From Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) — -1.69; -1.77 score on a scale
Phase 2 N=46 eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk
Depression · Major Depressive Disorder · Dysthymic Disorder
Primary: Hemoglobin A1c at 6 Months — 4.94; 4.88 % (percentage of total hemoglobin) — p=0.64
N/A N=666 Individualized Response to Vitamin D Treatment Study
Characteristics That Modify the Response to Cholecalciferol Treatment
Primary: Change in Serum 1,25(OH)2D Concentration — 2; -1 pg/mL
N/A N=2,280 Post Approval Study of the AcrySof® IQ ReSTOR® Toric IOLs
Aphakia · Presbyopia · Astigmatism
Primary: Rate of Eyes With Post-Surgical Intraocular Inflammation - By Eye - Cohort 2 — 5.6; 4.5 event rate per 1000 implants
Phase 2 N=40 Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis
Plastic Bronchitis · Protein-Losing Enteropathies · Healthy
Primary: Primary Endpoint: Number of Subjects That Develop New, Active Bleeding — 0 Participants